CM
LRMR icon

Caption Management’s Larimar Therapeutics LRMR Stock Holding History

Caption Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Buy
635,024
+219,730
+53% +$878K 0.02% 715
2025
Q4 		$1.58M Sell
415,294
-897,058
-68% -$3.49M 0.01% 913
2025
Q3 		$4.24M Buy
1,312,352
+623,062
+90% +$2.34M 0.03% 557
2025
Q2 		$1.99M Buy
+689,290
New +$1.6M 0.02% 714
2024
Q2 		– Sell
-142,900
Closed -$1.08M – 1364
2024
Q1 		$1.08M Buy
+142,900
New +$1.11M 0.02% 710

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caption Management's LRMR Position: Q1 2026 in Review

Caption Management increased its Larimar Therapeutics (LRMR) stake by 53% in Q1 2026, buying an estimated $878K and bringing the position to 635,024 shares worth $2.86M. The position accounts for 0.02% of the portfolio, ranked #715.

Caption Management first reported a position in LRMR in Q1 2024 and has held it in 5 quarters since. The position peaked at $4.24M in Q3 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Caption Management held 635,024 shares of Larimar Therapeutics worth $2.86M as of Q1 2026.
  • Caption Management bought 219,730 Larimar Therapeutics shares in Q1 2026, an estimated $878K.
  • Larimar Therapeutics made up 0.02% of Caption Management's portfolio in Q1 2026, its #715 holding.
  • Caption Management first reported a position in Larimar Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Caption Management's Larimar Therapeutics position peaked at $4.24M in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.